Displaying drugs 451 - 475 of 8039 in total
Ethotoin
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … The mechanism of action is probably very similar to that of phenytoin. ... seizure activity rather than to abolish the primary focus of seizure discharges. ... drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of …
Tenecteplase
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids...
Approved
Matched Description: … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine ... Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA …
Zaleplon
Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Approved
Illicit
Investigational
Matched Description: … Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of …
Teriflunomide
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and...
Approved
Matched Description: … Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting ... The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients ... It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically …
Rupatadine
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Scorpion (centruroides) immune Fab2 antivenin (equine)
Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 fragments that are derived from plasma of the horses immunized with venom of C. noxius, C. l. limpidus, C. l. tecomanus, and C. s. suffusus. It is intravenously administered patients with clinical signs of scorpion envenomation so...
Approved
Matched Description: … fragments that are derived from plasma of the horses immunized with venom of *C. noxius*, *C. l. limpidus ... Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 ... It is intravenously administered patients with clinical signs of scorpion envenomation so that the Fab …
Ripretinib
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … treatment with a minimum of 3 other kinase inhibitors. ... Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST ... [L13769]
It is the first drug approved as a fourth-line therapy in the specific setting of prior …
Tildrakizumab
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... A study was performed on the pharmacokinetics of this drug on various ethnicities. ... high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of …
Albendazole
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Approved
Vet approved
Eprosartan
Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.
Approved
Matched Description: … By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs …
Gemeprost
Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy . It is not FDA-approved but available in...
Approved
Withdrawn
Matched Description: … Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the ... suppositories and also used in combination with the antiprogestin and mifepristone for termination of …
Nitroprusside
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Approved
Investigational
Matched Description: … Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles …
Dexbrompheniramine
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Approved
Matched Description: … Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions …
Clavulanic acid
Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces clavuligerus. When it is combined with amoxicillin, clavulanic acid is...
Approved
Vet approved
Matched Description: … antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … due to the presence of specific activating EGFR mutations within the tumour cells. ... [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs …
Givosiran
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of ... Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of ... [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as …
Icodextrin
Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport...
Approved
Investigational
Matched Description: … It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal …
Lifitegrast
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Cabotegravir
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193]
Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … showed it had lower oral bioavailability than [dolutegravir],[A227668] which resulted in the development of …
Solriamfetol
Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label].
Approved
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … permeability of the blood-brain barrier, which allows for the passage of pro-inflammatory mediators ... This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single ... autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... of this debilitating disorder. ... The most common subtype of MoCD, type A, involves mutations in _MOCS1_ wherein the first step of molybdenum …
Flunarizine
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Description: … It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central ... and peripheral origin, and as an adjuvant in the therapy of epilepsy. …
Bilastine
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Approved
Investigational
Matched Description: … antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of …
Phenylpropanolamine
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Approved
Vet approved
Withdrawn
Displaying drugs 451 - 475 of 8039 in total